<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="863">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149924</url>
  </required_header>
  <id_info>
    <org_study_id>QL1012-002</org_study_id>
    <nct_id>NCT05149924</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment</brief_title>
  <official_title>A Multicenter, Randomized, Single-blind, Active-controlled, Phase III Clinical Study to Compare the Efficacy and Safety of QL1012(Recombinant Human Follicle-stimulating Hormone) and Gonal-f ® in Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted to confirm equivalence between QL1012 (a new biosimilar formulation of&#xD;
      Recombinant Human Follicle-stimulating Hormone) and Gonal-f® with respect to the number of&#xD;
      oocytes retrieved in women for assisted reproductive treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Actual">October 17, 2019</completion_date>
  <primary_completion_date type="Actual">October 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>36-38 hours after hCG administration</time_frame>
    <description>36-38 hours after hCG administration, transvaginal ultrasound-guided aspiration was performed as required, and the number of oocytes was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of r-hFSH administered</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of r-hFSH stimulation</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol concentration</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate of Oocytes</measure>
    <time_frame>Day 1 of IVF/ICSI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of high-quality embryos</measure>
    <time_frame>3 days after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>five to six weeks after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>35 ± 4 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>Ten weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>QL1012，Recombinant Human Follicle Stimulating Hormone for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1012</intervention_name>
    <description>Subcutaneous injection,starting dose within 75IU ~ 300IU determined by the age , maximum daily dose 450IU</description>
    <arm_group_label>QL1012，Recombinant Human Follicle Stimulating Hormone for Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-f ®</intervention_name>
    <description>Subcutaneous injection,starting dose within 75IU ~ 300IU determined by the age , maximum daily dose 450IU</description>
    <arm_group_label>Gonal-f ®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Aged 20 ~ 39 years(inclusive)&#xD;
&#xD;
          3. Body mass index (BMI) between 18~30 kg/m2(inclusive)&#xD;
&#xD;
          4. Regular menstrual cycle (25~35 days)&#xD;
&#xD;
          5. Basal FSH &lt; 10 IU/L (menstrual cycle day 2~5)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ≥3 previously completed IVF/ICSI-ET cycles without clinical pregnancy&#xD;
&#xD;
          2. History of ≥3 recurrent spontaneous miscarriages&#xD;
&#xD;
          3. Patients with high risk of ovarian hyperstimulation syndrome (OHSS)&#xD;
&#xD;
          4. Primary ovarian failure or poor responders to ovarian stimulation&#xD;
&#xD;
          5. Presence of pregnancy in previous 3 months&#xD;
&#xD;
          6. Presence of clinically significant systemic disease, endocrine disease or metabolic&#xD;
             abnormalities&#xD;
&#xD;
          7. History of malignant tumors of the ovary, breast, uterus, hypothalamus, pituitary&#xD;
             gland, etc.;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

